Valsts: Tanzānija
Valoda: angļu
Klimata pārmaiņas: Tanzania Medicinces & Medical Devices Authority
Pregabalin
Getz Pharma Private Limited, PAKISTAN
Antiepileptic drugs
Pregabalin
75
Capsules
Getz Pharma Private Limited, PAKISTAN
Physical description: Hard gelatin capsule with ivory opaque cap and yellow opaque body printed Getz logo and 75mg in black containing white powder; Local technical representative: Planet Pharmaceutical Limited (6099)
Registered/Compliant
2021-08-20
Effective date: 03/10/2022 TMDA/DMC/MRE/F/016 REV #:02 THEUNITEDREPUBLICOFTANZANIA MINISTRY OF HEALTH TANZANIA MEDICINES AND MEDICAL DEVICES AUTHORITY PUBLIC ASSESSMENT REPORT FOR GABICA TM 75 MG (PREGABALIN 75 MG) HARD GELATIN CAPSULES VERSION NUMBER 01, 03/01/2023 TMDA HEADQUARTERS, PLOT NO. 56/1, BLOCK E, KISASA B CENTRE, SWASWA ROAD, P. O. BOX 1253, DODOMA – TANZANIA, TELEPHONE: +255 (26) 2961989/2061990/+255 (22) 2450512/2450751/2452108, EMAIL: INFO@TMDA.OG.TZ, Website: WWW.TMDA.GO.TZ Toll free: 0800110084 Effective date: 03/10/2022 1 1. INTRODUCTION Gabica TM 75 mg is a generic medicine of Lyrica 75 mg hard capsules of Pfizer Limited, is an analogue of the neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin decreases central neuronal excitability by binding to an auxiliary subunit (α2-δ protein) of a voltage-gated calcium channel on neurons in the central nervous system. Pregabalin reduces the release of several neurotransmitters, including glutamate, noradrenaline, and substance. Gabica TM 75 mg is approved in Tanzania for use only in adult patients. 1.1 PRODUCT DETAILS Registration number TAN 21 HM 0430 Brand name Gabica TM 75 mg Generic name, strength, and form Each hard gelatin capsule contains 75 mg Pregabalin ATC classification ATC Code- N03AX16 (Anti–epileptics, other antiepileptics) Distribution category POM Country of origin Pakistan Associated product Gabica TM 150 mg and Gabica TM 50 mg Marketing Authorization Holder Getz Pharma (Pvt) Limited 29-30/27, Korangi Industrial Area, Karachi-74900 Pakistan Local Technical Representative Planet Pharmaceuticals Limited P. O. Box 38328, Dar es Salaam 1.2 ASSESSMENT PROCEDURE The application for registration of Gabica TM 75 mg was submitted on 23/07/2020. The product underwent full assessment. Assessment was completed in 3 (three) rounds of evaluation and the product was registered on 20/08/2021. 1.3 INFORMATION FOR USERS Visual description of the finished product Hard gelatin capsule with ivory opaque cap and yellow opaque body printed Getz l Izlasiet visu dokumentu